Taysha Gene Therapies (NASDAQ:TSHA) Hits New 52-Week Low – Time to Sell?Defense World · Oct 16, 2026
Taysha Gene Therapies (NASDAQ:TSHA) versus MediWound (NASDAQ:MDWD) Head to Head AnalysisDefense World · Oct 9, 2026
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)GlobeNewsWire · Oct 2, 2026
Taysha Gene Therapies Announces Multiple Encore Presentations Supporting TSHA-102 Rett Syndrome Clinical Program at the 55th Child Neurology Society Annual MeetingGlobeNewsWire · Oct 1, 2026
Taysha Gene Therapies: A Bull Case That Does Not Require The Fastest ApprovalSeeking Alpha · Sep 11, 2026
These 3 Risky Stocks Could Be Sitting on 100% UpsideMarketBeat · Sep 7, 2026Taysha Gene Therapies, Inc. is a biotech firm specializing in the creation and market introduction of gene therapies that utilize adeno-associated virus (AAV) vectors. Its core mission is to tackle inherited diseases affecting the central nervous system (CNS). The company's development pipeline features several key programs: TSHA-120 is aimed at giant axonal neuropathy; TSHA-102 is in development for Rett syndrome; TSHA-121 and TSHA-118 are both being advanced for CLN1 disease; TSHA-105 addresses SLC13A5 Deficiency; and TSHA-101 targets GM2 gangliosidosis.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 11, 2026 | -$0.11 | -$0.13 | Miss |
| May 6, 2026 | -$0.10 | -$0.12 | Miss |
| Mar 19, 2026 | -$0.11 | -$0.08 | Beat |
| Nov 4, 2025 | -$0.09 | -$0.09 | Beat |
| Aug 12, 2025 | -$0.07 | -$0.09 | Miss |
| May 15, 2025 | -$0.08 | -$0.08 | Beat |